Taysha Gene Therapies Inc
TSHA
Market Cap$411.94M
Close$
$-0.19
108.7% downside
Current Fair Value
108.7% downsideOvervalued by 108.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $411.94 Million |
|---|---|
| Enterprise Value | $345.85 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.96 |
| Beta | 0.38 |
| Outstanding Shares | 232,821,553 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.09 |
|---|---|
| PEG | 5.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 34.88 |
| Enterprise Value to EBIT | -3.96 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 1.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Taysha Gene Therapies Inc
38 employeesTaysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined i...